Small Cell Tumors, Lymphomas, and Sertoli Cell and Leydig Cell Tumors of the Bladder, Prostate, and Testis

  • Chris M. Bacon
  • Alex Freeman
Chapter

Keywords

Sertoli Cell Small Cell Carcinoma Malt Lymphoma Luteinizing Hormone Receptor Leydig Cell Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252–260.PubMedGoogle Scholar
  2. 2.
    Colevas AD, Kantoff PW, DeWolf WC, et al. Malignant lymphoma of the genitourinary tract. In: Vogelzanf NJ, Shipley WU, Scardino PT, et al., eds. Comprehensive Textbook of Genitourinary Oncology, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000:1120–1132.Google Scholar
  3. 3.
    Jaffe ES, Harris NL, Stein H, et al., eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.Google Scholar
  4. 4.
    Shahab N, Doll DC. Testicular lymphoma. Semin Oncol 1999;26:259–269.PubMedGoogle Scholar
  5. 5.
    Moller MB, d’Amore F, Christensen BE. Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis. Eur J Cancer 1994;30A:1760–1764.PubMedGoogle Scholar
  6. 6.
    Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the international extranodal lymphoma study group. J Clin Oncol 2003;21:20–27.PubMedGoogle Scholar
  7. 7.
    Visco C, Medeiros LJ, Mesina OM, et al. Non-Hodgkin’s lymphoma affecting the testis: Is it curable with doxorubicin-based therapy? Clin Lymphoma 2001;2:40–46.PubMedGoogle Scholar
  8. 8.
    Seymour JF, Solomon B, Wolf MM, et al. Primary large-cell non-Hodgkin’s lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. Clin Lymphoma 2001;2:109–115.PubMedGoogle Scholar
  9. 9.
    Linassier C, Desablens B, Lefrancq T, et al. Stage I-IIe primary non-Hodgkin’s lymphoma of the testis: results of a prospective trial by the GOELAMS study group. Clin Lymphoma 2002;3:167–172.PubMedGoogle Scholar
  10. 10.
    Ferry JA, Harris NL, Young RH, et al. Malignant lymphoma of the testis, epididymis, and spermatic cord. A clinicopathologic study of 69 cases with immunophenotypic analysis. Am J Surg Pathol 1994;18:376–390.PubMedCrossRefGoogle Scholar
  11. 11.
    Wilkins BS, Williamson JM, O’Brien CJ. Morphological and immunohistological study of testicular lymphomas. Histopathology 1989;15:147–156.PubMedGoogle Scholar
  12. 12.
    Lagrange JL, Ramaioli A, Theodore CH, et al. Non-Hodgkin’s lymphoma of the testis: a retrospective study of 84 patients treated in the French anticancer centres. Ann Oncol 2001;12:1313–1319.PubMedGoogle Scholar
  13. 13.
    Fonseca R, Habermann TM, Colgan JP, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 2000;88:154–161.PubMedGoogle Scholar
  14. 14.
    Dogan A, Bagdi E, Munson P, et al. CD10 and bcl-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000;24:846–852.PubMedGoogle Scholar
  15. 15.
    Hyland J, Lasota J, Jasinski M, et al. Molecular pathological analysis of testicular diffuse large cell lymphomas. Hum Pathol 1998;29:1231–1239.PubMedGoogle Scholar
  16. 16.
    Lossos IS, Okada CY, Tibshirani R, et al. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. Blood 2000;95:1797–1803.PubMedGoogle Scholar
  17. 17.
    Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001;412:341–346.PubMedGoogle Scholar
  18. 18.
    Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.PubMedGoogle Scholar
  19. 19.
    Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.PubMedGoogle Scholar
  20. 20.
    Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68–74.PubMedGoogle Scholar
  21. 21.
    de Leval L, Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology 2003;43:509–528.PubMedGoogle Scholar
  22. 22.
    Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003;101:78–84.PubMedGoogle Scholar
  23. 23.
    Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the international prognostic index improves patient risk stratification in diffuse large b-cell lymphoma. Blood 2002;99:1136–1143.PubMedGoogle Scholar
  24. 24.
    Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.PubMedGoogle Scholar
  25. 25.
    Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of bcl-2, bcl-6, and myc rearrangements in diffuse large B-cell lymphoma. Blood 1998;92:3152–3162.PubMedGoogle Scholar
  26. 26.
    Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood 1997;90:244–251.PubMedGoogle Scholar
  27. 27.
    Barrans SL, Evans PA, O’Connor SJ, et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res 2003;9:2133–2139.PubMedGoogle Scholar
  28. 28.
    Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002;99:2285–2290.PubMedGoogle Scholar
  29. 29.
    Monni O, Joensuu H, Franssila K, et al. Bcl-2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997;90:1168–1174.PubMedGoogle Scholar
  30. 30.
    Lambrechts AC, Looijenga LH, van’t Veer MB, et al. Lymphomas with testicular localisation show a consistent bcl-2 expression without a translocation (14;18): a molecular and immunohistochemical study. Br J Cancer 1995;71:73–77.PubMedGoogle Scholar
  31. 31.
    Ye BH, Chaganti S, Chang CC, et al. Chromosomal translocations cause deregulated bcl-6 expression by promoter substitution in B cell lymphoma. EMBO J 1995;14:6209–6217.PubMedGoogle Scholar
  32. 32.
    Pasqualucci L, Migliazza A, Basso K, et al. Mutations of the bcl-6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 2003;101:2914–2923.PubMedGoogle Scholar
  33. 33.
    Ichikawa A, Kinoshita T, Watanabe T, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997;337:529–534.PubMedGoogle Scholar
  34. 34.
    Houldsworth J, Mathew S, Rao PH, et al. Rel proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 1996;87:25–29.PubMedGoogle Scholar
  35. 35.
    Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861–1874.PubMedGoogle Scholar
  36. 36.
    Riemersma SA, Jordanova ES, Schop RF, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000;96:3569–3577.PubMedGoogle Scholar
  37. 37.
    Jordanova ES, Riemersma SA, Philippo K, et al. Beta 2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system. Int J Cancer 2003;103:393–398.PubMedGoogle Scholar
  38. 38.
    Horstmann WG, Timens W. Lack of adhesion molecules in testicular diffuse centroblastic and immunoblastic B cell lymphomas as a contributory factor in malignant behaviour. Virchows Arch 1996;429:83–90.PubMedGoogle Scholar
  39. 39.
    Zouhair A, Weber D, Belkacemi Y, et al. Outcome and patterns of failure in testicular lymphoma: a multicenter rare cancer network study. Int J Radiat Oncol Biol Phys 2002;52:652–656.PubMedGoogle Scholar
  40. 40.
    Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation—a population-based study of 1575 cases. Br J Haematol 2004;124:151–159.PubMedGoogle Scholar
  41. 41.
    Connors JM, Klimo P, Voss N, et al. Testicular lymphoma: improved outcome with early brief chemotherapy. J Clin Oncol 1988;6:776–781.PubMedGoogle Scholar
  42. 42.
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.PubMedGoogle Scholar
  43. 43.
    Dalle JH, Mechinaud F, Michon J, et al. Testicular disease in childhood B-cell non-Hodgkin’s lymphoma: the French society of pediatric oncology experience. J Clin Oncol 2001;19:2397–2403.PubMedGoogle Scholar
  44. 44.
    Kim TH, Hargreaves HK, Chan WC, et al. Sequential testicular biopsies in childhood acute lymphocytic leukemia. Cancer 1986;57:1038–1041.PubMedGoogle Scholar
  45. 45.
    Grundy RG, Leiper AD, Stanhope R, et al. Survival and endocrine outcome after testicular relapse in acute lymphoblastic leukaemia. Arch Dis Child 1997;76:190–196.PubMedCrossRefGoogle Scholar
  46. 46.
    Pileri SA, Sabattini E, Rosito P, et al. Primary follicular lymphoma of the testis in childhood: an entity with peculiar clinical and molecular characteristics. J Clin Pathol 2002;55:684–688.PubMedGoogle Scholar
  47. 47.
    Ferry JA, Young RH, Scully RE. Testicular and epididymal plasmacytoma: a report of 7 cases, including three that were the initial manifestation of plasma cell myeloma. Am J Surg Pathol 1997;21:590–598.PubMedGoogle Scholar
  48. 48.
    Anghel G, Petti N, Remotti D, et al. Testicular plasmacytoma: report of a case and review of the literature. Am J Hematol 2002;71:98–104.PubMedGoogle Scholar
  49. 49.
    Kim YB, Chang SK, Yang WI, et al. Primary NK/T cell lymphoma of the testis. A case report and review of the literature. Acta Haematol 2003;109:95–100.PubMedGoogle Scholar
  50. 50.
    Henley JD, Ferry J, Ulbright TM. Miscellaneous rare paratesticular tumors. Semin Diagn Pathol 2000;17:319–339.PubMedGoogle Scholar
  51. 51.
    Vega F, Medeiros LJ, Abruzzo LV. Primary paratesticular lymphoma: a report of 2 cases and review of literature. Arch Pathol Lab Med 2001;125:428–432.PubMedGoogle Scholar
  52. 52.
    Givler RL. Involvement of the bladder in leukemia and lymphoma. J Urol 1971;105:667–670.PubMedGoogle Scholar
  53. 53.
    Kempton CL, Kurtin PJ, Inwards DJ, et al. Malignant lymphoma of the bladder: evidence from 36 cases that low-grade lymphoma of the MALT-type is the most common primary bladder lymphoma. Am J Surg Pathol 1997;21:1324–1333.PubMedGoogle Scholar
  54. 54.
    Ohsawa M, Aozasa K, Horiuchi K, et al. Malignant lymphoma of bladder. Report of three cases and review of the literature. Cancer 1993;72:1969–1974.PubMedGoogle Scholar
  55. 55.
    Bates AW, Norton AJ, Baithun SI. Malignant lymphoma of the urinary bladder: a clinicopathological study of 11 cases. J Clin Pathol 2000;53:458–461.PubMedGoogle Scholar
  56. 56.
    Al-Maghrabi J, Kamel-Reid S, Jewett M, et al. Primary low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type arising in the urinary bladder: report of 4 cases with molecular genetic analysis. Arch Pathol Lab Med 2001;125:332–336.PubMedGoogle Scholar
  57. 57.
    Pawade J, Banerjee SS, Harris M, et al. Lymphomas of mucosa-associated lymphoid tissue arising in the urinary bladder. Histopathology 1993;23:147–151.PubMedGoogle Scholar
  58. 58.
    Du MQ, Isaccson PG. Gastric MALT lymphoma: From aetiology to treatment. Lancet Oncol 2002;3:97–104.PubMedGoogle Scholar
  59. 59.
    Krober SM, Aepinus C, Ruck P, et al. Extranodal marginal zone B cell lymphoma of MALT type involving the mucosa of both the urinary bladder and stomach. J Clin Pathol 2002;55:554–557.PubMedGoogle Scholar
  60. 60.
    Streubel B, Lamprecht A, Dierlamm J, et al. T(14;18)(q32;q21) involving IgH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003;101:2335–2339.PubMedGoogle Scholar
  61. 61.
    Tsang RW, Gospodarowicz MK, Pintilie M, et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 2001;50:1258–1264.PubMedGoogle Scholar
  62. 62.
    van den Bosch J, Kropman RF, Blok P, et al. Disappearance of a mucosa-associated lymphoid tissue (MALT) lymphoma of the urinary bladder after treatment for Helicobacter pylori. Eur J Haematol 2002;68:187–188.PubMedGoogle Scholar
  63. 63.
    Oscier D, Bramble J, Hodges E, et al. Regression of mucosa-associated lymphoid tissue lymphoma of the bladder after antibiotic therapy. J Clin Oncol 2002;20:882.PubMedGoogle Scholar
  64. 64.
    Patel DR, Gomez GA, Henderson ES, et al. Primary prostatic involvement in non-Hodgkin lymphoma. Urology 1988;32:96–98.PubMedGoogle Scholar
  65. 65.
    Sarris A, Dimopoulos M, Pugh W, et al. Primary lymphoma of the prostate: good outcome with doxorubicin-based combination chemotherapy. J Urol 1995;153:1852–1854.PubMedGoogle Scholar
  66. 66.
    Zein TA, Huben R, Lane W, et al. Secondary tumors of the prostate. J Urol 1985;133:615–616.PubMedGoogle Scholar
  67. 67.
    Bostwick DG, Iczkowski KA, Amin MB, et al. Malignant lymphoma involving the prostate: report of 62 cases. Cancer 1998;83:732–738.PubMedGoogle Scholar
  68. 68.
    Winstanley AM, Sandison A, Bott SR, et al. Incidental findings in pelvic lymph nodes at radical prostatectomy. J Clin Pathol 2002;55:623–626.PubMedGoogle Scholar
  69. 69.
    Weir EG, Epstein JI. Incidental small lymphocytic lymphoma/chronic lymphocytic leukemia in pelvic lymph nodes excised at radical prostatectomy. Arch Pathol Lab Med 2003;127:567–572.PubMedGoogle Scholar
  70. 70.
    Tomaru U, Ishikura H, Kon S, et al. Primary lymphoma of the prostate with features of low grade B-cell lymphoma of mucosa associated lymphoid tissue: a rare cause of urinary obstruction. J Urol 1999;162:496–497.PubMedGoogle Scholar
  71. 71.
    Bogdan CA, Alexander AA, Gorny MK, et al. Chronic lymphocytic leukemia with prostate infiltration mediated by specific clonal membrane-bound IgM. Cancer Res 2003;63:2067–2071.PubMedGoogle Scholar
  72. 72.
    Leung TW, Tung SY, Sze WK, et al. Primary non-Hodgkin’s lymphoma of the prostate. Clin Oncol (R Coll Radiol) 1997;9:264–266.Google Scholar
  73. 73.
    Entz-Werle N, Marcellin L, Becmeur F, et al. The urinary bladder: an extremely rare location of pediatric neuroblastoma. J Pediatr Surg 2003;38:E10–12.PubMedGoogle Scholar
  74. 74.
    Yokoyama S, Hirakawa H, Ueno S, et al. Neuroblastoma of the urinary bladder, preclinically detected by mass screening. Pediatrics 1999;103:e67.PubMedGoogle Scholar
  75. 75.
    Kruger S, Schmidt H, Kausch I, et al. Primitive neuroectodermal tumor (PNET) of the urinary bladder. Pathol Res Pract 2003;199:751–754.PubMedGoogle Scholar
  76. 76.
    Ijiri R, Tanaka Y, Kou K, et al. Bladder origin neuroblastoma detected by mass screening. Urology 1998;52:1139–1141.PubMedGoogle Scholar
  77. 77.
    Gupta A, Menon P, Rao KL, et al. Wilms’ tumor: Transureteral intravesical extension and presentation as urinary retention. J Pediatr Surg 2003;38:E4–5.PubMedGoogle Scholar
  78. 78.
    Mitchell CS, Yeo TA. Noninvasive botryoid extension of Wilms’ tumor into the bladder. Pediatr Radiol 1997;27:818–820.PubMedGoogle Scholar
  79. 79.
    Williams DH, Hua VN, Chowdhry AA, et al. Synovial sarcoma of the prostate. J Urol 2004;171:2376.PubMedGoogle Scholar
  80. 80.
    Iwasaki H, Ishiguro M, Ohjimi Y, et al. Synovial sarcoma of the prostate with t(x;18)(p11.2;q11.2). Am J Surg Pathol 1999;23:220–226.PubMedGoogle Scholar
  81. 81.
    Cunningham JA, Fendler JP, Nichols PJ, et al. Metastatic malignant melanoma: an unusual case presentation. Urology 1994;44:924–926.PubMedGoogle Scholar
  82. 82.
    Demirkesen O, Yaycioglu O, Uygun N, et al. A case of metastatic malignant melanoma presenting with hematuria. Urol Int 2000;64:118–120.PubMedGoogle Scholar
  83. 83.
    Lee CS, Komenaka IK, Hurst-Wicker KS, et al. Management of metastatic malignant melanoma of the bladder. Urology 2003;62:351.Google Scholar
  84. 84.
    Nesi G, Vezzosi V, Amorosi A, et al. Paraganglioma of the urinary bladder. Urol Int 1996;56:250–253.PubMedGoogle Scholar
  85. 85.
    Cramer SF, Aikawa M, Cebelin M. Neurosecretory granules in small cell invasive carcinoma of the urinary bladder. Cancer 1981;47:724–730.PubMedGoogle Scholar
  86. 86.
    Fujita K, Nishimura K, Nonomura N, et al. Early stage small cell carcinoma of the urinary bladder. Int J Urol 2001;8:643–644.PubMedGoogle Scholar
  87. 87.
    Grignon DJ, Ro JY, Ayala AG, et al. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases. Cancer 1992;69:527–536.PubMedGoogle Scholar
  88. 88.
    Trias I, Algaba F, Condom E, et al. Small cell carcinoma of the urinary bladder. Presentation of 23 cases and review of 134 published cases. Eur Urol 2001;39:85–90.PubMedGoogle Scholar
  89. 89.
    Partanen S, Asikainen U. Oat cell carcinoma of the urinary bladder with ectopic adrenocorticotropic hormone production. Hum Pathol 1985;16:313–315.PubMedGoogle Scholar
  90. 90.
    Reyes CV, Soneru I. Small cell carcinoma of the urinary bladder with hypercalcemia. Cancer 1985;56:2530–2533.PubMedGoogle Scholar
  91. 91.
    Kim JC, Kim KH, Jung S. Small cell carcinoma of the urinary bladder: CT and MR imaging findings. Korean J Radiol 2003;4:130–135.PubMedCrossRefGoogle Scholar
  92. 92.
    Kim JC. CT features of bladder small cell carcinoma. Clin Imaging 2004;28:201–205.PubMedGoogle Scholar
  93. 93.
    Yamaguchi T, Imamura Y, Shimamoto T, et al. Small cell carcinoma of the bladder. Two cases diagnosed by urinary cytology. Acta Cytol 2000;44:403–409.PubMedGoogle Scholar
  94. 94.
    Ali SZ, Reuter VE, Zakowski MF. Small cell neuroendocrine carcinoma of the urinary bladder. A clinicopathologic study with emphasis on cytologic features. Cancer 1997;79:356–361.PubMedGoogle Scholar
  95. 95.
    Algaba F, Sauter G, Schoenberg MP. Small cell carcinoma. In: Eble JN, Sauter G, Epstein JI, et al., eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004:135–136.Google Scholar
  96. 96.
    Chuang CK, Liao SK. A retrospective immunohistochemical and clinicopathological study of small cell carcinomas of the urinary tract. Chang Gung Med J 2003;26:26–33.PubMedGoogle Scholar
  97. 97.
    Kaufmann O, Georgi T, Dietel M. Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections. Hum Pathol 1997;28:1373–1378.PubMedGoogle Scholar
  98. 98.
    Iczkowski KA, Shanks JH, Allsbrook WC, et al. Small cell carcinoma of urinary bladder is differentiated from urothelial carcinoma by chromogranin expression, absence of CD44 variant 6 expression, a unique pattern of cytokeratin expression, and more intense gammaenolase expression. Histopathology 1999;35:150–156.PubMedGoogle Scholar
  99. 99.
    Blomjous CE, Vos W, De Voogt HJ, et al. Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases. Cancer 1989;64:1347–1357.PubMedGoogle Scholar
  100. 100.
    Terracciano L, Richter J, Tornillo L, et al. Chromosomal imbalances in small cell carcinomas of the urinary bladder. J Pathol 1999;189:230–235.PubMedGoogle Scholar
  101. 101.
    Selli C, Gelmini S, Scott CA, et al. Evidence for elevated telomerase activity in small cell carcinoma of the bladder. Urology 2000;56:331.PubMedGoogle Scholar
  102. 102.
    Abbas F, Civantos F, Benedetto P, et al. Small cell carcinoma of the bladder and prostate. Urology 1995;46:617–630.PubMedGoogle Scholar
  103. 103.
    Mackey JR, Au HJ, Hugh J, et al. Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival. J Urol 1998;159:1624–1629.PubMedGoogle Scholar
  104. 104.
    Lohrisch C, Murray N, Pickles T, et al. Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer 1999;86:2346–2352.PubMedGoogle Scholar
  105. 105.
    Nejat RJ, Purohit R, Goluboff ET, et al. Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy. 2001;6:53–55.Google Scholar
  106. 106.
    Lopez Cubillana P, Martinez Barba E, Prieto A, et al. Oat-cell carcinoma of the prostate. Diagnosis, prognosis and therapeutic implications. Urol Int 2001;67:209–212.PubMedGoogle Scholar
  107. 107.
    Helpap B, Kollermann J. Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch 1999;434:385–391.PubMedGoogle Scholar
  108. 108.
    Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999;39:135–148.PubMedGoogle Scholar
  109. 109.
    diSant’Agnese PA, Egevad L, Epstein JI, et al. Neuroendocrine tumours. In: Eble JN, Sauter G, Epstein JI, et al., eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004:207–208.Google Scholar
  110. 110.
    Spieth ME, Lin YG, Nguyen TT. Diagnosing and treating small-cell carcinomas of prostatic origin. Clin Nucl Med 2002;27:11–17.PubMedGoogle Scholar
  111. 111.
    Agoff SN, Lamps LW, Philip AT, et al. Thyroid. transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 2000;13:238–242.PubMedGoogle Scholar
  112. 112.
    Ordonez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol 2000;24:1217–1223.PubMedGoogle Scholar
  113. 113.
    Ito T, Yamamoto S, Ohno Y, et al. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence. Oncol Rep 2001;8:1221–1224.PubMedGoogle Scholar
  114. 114.
    Amato RJ, Logothetis CJ, Hallinan R, et al. Chemotherapy for small cell carcinoma of pro-static origin. J Urol 1992;147:935–937.PubMedGoogle Scholar
  115. 115.
    El-Sherbiny MT, El-Mekresh MH, El-Baz MA, et al. Paediatric lower urinary tract rhabdomyosarcoma: a single-centre experience of 30 patients. BJU Int 2000;86:260–267.PubMedGoogle Scholar
  116. 116.
    Konety BR, Schneck FX. Botryoid rhabdomyosarcoma of the bladder. Urology 1997;50:604–605.PubMedGoogle Scholar
  117. 117.
    Poggiani C, Teani M, Auriemma A, et al. Sonographic detection of rhabdomyosarcoma of the urinary bladder. Eur J Ultrasound 2001;13:35–39.PubMedGoogle Scholar
  118. 118.
    Kumar S, Perlman E, Harris CA, et al. Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffinembedded tissues. Mod Pathol 2000;13:988–993.PubMedGoogle Scholar
  119. 119.
    Lee W, Han K, Harris CP, et al. Detection of aneuploidy and possible deletion in paraffin-embedded rhabdomyosarcoma cells with FISH. Cancer Genet Cytogenet 1993;68:99–103.PubMedGoogle Scholar
  120. 120.
    Bridge JA, Liu J, Weibolt V, et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an inter-group rhabdomyosarcoma study. Genes Chromosomes Cancer 2000;27:337–344.PubMedGoogle Scholar
  121. 121.
    Raney B Jr, Heyn R, Hays DM, et al. Sequelae of treatment in 109 patients followed for 5 to 15 years after diagnosis of sarcoma of the bladder and prostate. A report from the Intergroup Rhabdomyosarcoma Study Committee. Cancer 1993;71:2387–2394.PubMedGoogle Scholar
  122. 122.
    Kaefer M, Rink RC. Genitourinary rhabdomyosarcoma. Treatment options. Urol Clin North Am 2000;27:471–487.PubMedGoogle Scholar
  123. 123.
    Ashlock R, Johnstone PA. Treatment modalities of bladder/prostate rhabdomyosarcoma: a review. Prostate Cancer Prostatic Dis 2003;6:112–120.PubMedGoogle Scholar
  124. 124.
    Leuschner I, Harms D, Mattke A, et al. Rhabdomyosarcoma of the urinary bladder and vagina: a clinicopathologic study with emphasis on recurrent disease: a report from the Kiel Pediatric Tumor Registry and the German CWS Study. Am J Surg Pathol 2001;25:856–864.PubMedGoogle Scholar
  125. 125.
    Ulbright TM, Srigley JR, Reuter VE, et al. Sex cord-stromal tumors of the testis with entrapped germ cells: a lesion mimicking unclassified mixed germ cell sex cord-stromal tumors. Am J Surg Pathol 2000;24:535–542.PubMedGoogle Scholar
  126. 126.
    Mikuz G, Schwarz S, Hopfel-Kreiner I, et al. Leydig cell tumor of the testis. Morphological and endocrinological investigations in two cases. Eur Urol 1980;6:293–300.PubMedGoogle Scholar
  127. 127.
    Kim I, Young RH, Scully RE. Leydig cell tumors of the testis. A clinicopathological analysis of 40 cases and review of the literature. Am J Surg Pathol 1985;9:177–192.PubMedGoogle Scholar
  128. 128.
    Shimp WS, Schultz AL, Hastings JR, et al. Leydigcell tumor of the testis with gynecomastia and elevated estrogen levels. Am J Clin Pathol 1977;67:562–566.PubMedGoogle Scholar
  129. 129.
    Caldamone AA, Altebarmakian V, Frank IN, et al. Leydig cell tumor of testis. Urology 1979;14:39–43.PubMedGoogle Scholar
  130. 130.
    Akman H, Ege G, Yildiz S, et al. Incidental bilateral Leydig cell tumor of the testes. Urol Int 2003;71:316–318.PubMedGoogle Scholar
  131. 131.
    Mahon FB, Jr., Gosset F, Trinity RG, et al. Malignant interstitial cell testicular tumor. Cancer 1973;31:1208–1212.PubMedGoogle Scholar
  132. 132.
    Grem JL, Robins HI, Wilson KS, et al. Metastatic Leydig cell tumor of the testis. Report of three cases and review of the literature. Cancer 1986;58:2116–2119.PubMedGoogle Scholar
  133. 133.
    De Kretser DM. Crystals of Reinke in the nuclei of human testicular interstitial cells. Experientia 1968;24:587–588.PubMedGoogle Scholar
  134. 134.
    Ulbright TM, Srigley JR, Hatzianastassiou DK, et al. Leydig cell tumors of the testis with unusual features: Adipose differentiation, calcification with ossification, and spindle-shaped tumor cells. Am J Surg Pathol 2002;26:1424–1433.PubMedGoogle Scholar
  135. 135.
    McCluggage WG, Shanks JH, Arthur K, et al. Cellular proliferation and nuclear ploidy assessments augment established prognostic factors in predicting malignancy in testicular Leydig cell tumours. Histopathology 1998;33:361–368.PubMedGoogle Scholar
  136. 136.
    Palazzo JP, Petersen RO, Young RH, et al. Deoxyribonucleic acid flow cytometry of testicular Leydig cell tumors. J Urol 1994;152:415–417.PubMedGoogle Scholar
  137. 137.
    Cheville JC, Sebo TJ, Lager DJ, et al. Leydig cell tumor of the testis: a clinicopathologic, DNA content, and MIB-1 comparison of nonmetastasizing and metastasizing tumors. Am J Surg Pathol 1998;22:1361–1367.PubMedGoogle Scholar
  138. 138.
    Hekimgil M, Altay B, Yakut BD, et al. Leydig cell tumor of the testis: comparison of histopathological and immunohistochemical features of three azoospermic cases and one malignant case. Pathol Int 2001;51:792–796.PubMedGoogle Scholar
  139. 139.
    Iczkowski KA, Bostwick DG, Roche PC, et al. Inhibin A is a sensitive and specific marker for testicular sex cord-stromal tumors. Mod Pathol 1998;11:774–779.PubMedGoogle Scholar
  140. 140.
    Augusto D, Leteurtre E, De La Taille A, et al. Calretinin: a valuable marker of normal and neoplastic Leydig cells of the testis. Appl Immunohistochem Mol Morphol 2002;10:159–162.PubMedGoogle Scholar
  141. 141.
    Stewart CJ, Nandini CL, Richmond JA. Value of A103 (Melan-A) immunostaining in the differential diagnosis of ovarian sex cord stromal tumours. J Clin Pathol 2000;53:206–211.PubMedGoogle Scholar
  142. 142.
    Yao DX, Soslow RA, Hedvat CV, et al. Melan-A (A103) and inhibin expression in ovarian neoplasms. Appl Immunohistochem Mol Morphol 2003;11:244–249.PubMedGoogle Scholar
  143. 143.
    McCluggage WG, Shanks JH, Whiteside C, et al. Immunohistochemical study of testicular sex cord-stromal tumors, including staining with anti-inhibin antibody. Am J Surg Pathol 1998;22:615–619.PubMedGoogle Scholar
  144. 144.
    Wilson PO, Barber PC, Hamid QA, et al. The immunolocalization of protein gene product 9.5 using rabbit polyclonal and mouse monoclonal antibodies. Br J Exp Pathol 1988;69:91–104.PubMedGoogle Scholar
  145. 145.
    Wu SM, Leschek EW, Rennert OM, et al. Luteinizing hormone receptor mutations in disorders of sexual development and cancer. Front Biosci 2000;5:D343–352.PubMedGoogle Scholar
  146. 146.
    Liu G, Duranteau L, Carel JC, et al. Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor. N Engl J Med 1999;341:1731–1736.PubMedGoogle Scholar
  147. 147.
    Canto P, Soderlund D, Ramon G, et al. Mutational analysis of the luteinizing hormone receptor gene in two individuals with Leydig cell tumors. Am J Med Genet 2002;108:148–152.PubMedGoogle Scholar
  148. 148.
    Vieira TC, Cerutti JM, Dias da Silva MR, et al. Absence of activating mutations in the hot spots of the LH receptor and Gs-alpha genes in Leydig cell tumors. J Endocrinol Invest 2002;25:598–602.PubMedGoogle Scholar
  149. 149.
    Wegner HE, Herbst H, Andresen R, et al. Leydig cell tumor recurrence after enucleation. J Urol 1996;156:1443–1444.PubMedGoogle Scholar
  150. 150.
    Wegner HE, Dieckmann KP, Herbst H, et al. Leydig cell tumor—comparison of results of radical and testis-sparing surgery in a single center. Urol Int 1997;59:170–173.PubMedCrossRefGoogle Scholar
  151. 151.
    Masoudi JF, Van Arsdalen K, Rovner ES. Organsparing surgery for bilateral Leydig cell tumor of the testis. Urology 1999;54:744.PubMedGoogle Scholar
  152. 152.
    Merlini E, Seymandi PL, Betta PG, et al. Testis sparing enucleation of a Leydig-cell tumour in a boy. Pediatr Med Chir 2003;25:63–65.PubMedGoogle Scholar
  153. 153.
    Farkas LM, Szekely JG, Pusztai C, et al. High frequency of metastatic Leydig cell testicular tumours. Oncology 2000;59:118–121.PubMedGoogle Scholar
  154. 154.
    Mosharafa AA, Foster RS, Bihrle R, et al. Does retroperitoneal lymph node dissection have a curative role for patients with sex cordstromal testicular tumors? Cancer 2003;98:753–757.PubMedGoogle Scholar
  155. 155.
    Bertram KA, Bratloff B, Hodges GF, et al. Treatment of malignant Leydig cell tumor. Cancer 1991;68:2324–2329.PubMedGoogle Scholar
  156. 156.
    Dieckmann KP, Loy V. Response of metastasized sex cord gonadal stromal tumor of the testis to cisplatin-based chemotherapy. J Urol 1994;151:1024–1026.PubMedGoogle Scholar
  157. 157.
    Wysocka B, Serkies K, Debniak J, et al. Sertoli cell tumor in androgen insensitivity syndrome—a case report. Gynecol Oncol 1999;75:480–483.PubMedGoogle Scholar
  158. 158.
    Rodewald A, Kittner T, Hahn G. The Carney complex: a rare differential diagnosis in cases with pituitary adenoma and testicular Sertoli cell tumour. Clin Radiol 2001;56:993–996.PubMedGoogle Scholar
  159. 159.
    Liu P, Thorner P. Sonographic appearance of Sertoli cell tumour: with pathologic correlation. Pediatr Radiol 1993;23:127–128.PubMedGoogle Scholar
  160. 160.
    Gierke CL, King BF, Bostwick DG, et al. Large-cell calcifying Sertoli cell tumor of the testis: appearance at sonography. AJR Am J Roentgenol 1994;163:373–375.PubMedGoogle Scholar
  161. 161.
    Young RH, Koelliker DD, Scully RE. Sertoli cell tumors of the testis, not otherwise specified: a clinicopathologic analysis of 60 cases. Am J Surg Pathol 1998;22:709–721.PubMedGoogle Scholar
  162. 162.
    Chang B, Borer JG, Tan PE, et al. Large-cell calcifying Sertoli cell tumor of the testis: case report and review of the literature. Urology 1998;52:520–522; discussion 522–523.PubMedGoogle Scholar
  163. 163.
    Giglio M, Medica M, De Rose AF, et al. Testicular Sertoli cell tumours and relative sub-types. Analysis of clinical and prognostic features. Urol Int 2003;70:205–210.PubMedGoogle Scholar
  164. 164.
    Terayama K, Hirokawa M, Shimizu M, et al. Sertoli cell tumor of the testis. Report of a case with imprint cytology findings. Acta Cytol 1998;42:1458–1460.PubMedGoogle Scholar
  165. 165.
    McLaren K, Thomson D. Localization of S-100 protein in a Leydig and Sertoli cell tumour of testis. Histopathology 1989;15:649–652.PubMedGoogle Scholar
  166. 166.
    Henley JD, Young RH, Ulbright TM. Malignant Sertoli cell tumors of the testis: a study of 13 examples of a neoplasm frequently misinterpreted as seminoma. Am J Surg Pathol 2002;26:541–550.PubMedGoogle Scholar
  167. 167.
    Tetu B, Ro JY, Ayala AG. Large cell calcifying Sertoli cell tumor of the testis. A clinicopathologic, immunohistochemical, and ultrastructural study of two cases. Am J Clin Pathol 1991;96:717–722.PubMedGoogle Scholar
  168. 168.
    Proppe KH, Scully RE. Large-cell calcifying Sertoli cell tumor of the testis. Am J Clin Pathol 1980;74:607–619.PubMedGoogle Scholar
  169. 169.
    Kratzer SS, Ulbright TM, Talerman A, et al. Large cell calcifying Sertoli cell tumor of the testis: contrasting features of six malignant and six benign tumors and a review of the literature. Am J Surg Pathol 1997;21:1271–1280.PubMedGoogle Scholar
  170. 170.
    Cano-Valdez AM, Chanona-Vilchis J, Dominguez-Malagon H. Large cell calcifying Sertoli cell tumor of the testis: a clinicopathological, immunohistochemical, and ultrastructural study of two cases. Ultrastruct Pathol 1999;23:259–265.PubMedGoogle Scholar
  171. 171.
    Nogales FF, Andujar M, Zuluaga A, et al. Malignant large cell calcifying Sertoli cell tumor of the testis. J Urol 1995;153:1935–1937.PubMedGoogle Scholar
  172. 172.
    Bufo P, Pennella A, Serio G, et al. Malignant large cell calcifying Sertoli cell tumor of the testis (LCCSCTT). Report of a case in an elderly man and review of the literature. Pathologica 1999;91:107–114.PubMedGoogle Scholar
  173. 173.
    De Raeve H, Schoonooghe P, Wibowo R, et al. Malignant large cell calcifying Sertoli cell tumor of the testis. Pathol Res Pract 2003;199:113–117.PubMedGoogle Scholar
  174. 174.
    Anderson GA. Sclerosing Sertoli cell tumor of the testis: a distinct histological subtype. J Urol 1995;154:1756–1758.PubMedGoogle Scholar
  175. 175.
    Gravas S, Papadimitriou K, Kyriakidis A. Sclerosing Sertoli cell tumor of the testis—a case report and review of the literature. Scand J Urol Nephrol 1999;33:197–199.PubMedGoogle Scholar
  176. 176.
    Knoke I, Jakubiczka S, Ottersen T, et al. A(870)E mutation of the androgen receptor gene in a patient with complete androgen insensitivity syndrome and Sertoli cell tumor. Cancer Genet Cytogenet 1997;98:139–141.PubMedGoogle Scholar
  177. 177.
    Ko HM, Chung JH, Lee JH, et al. Androgen receptor gene mutation associated with complete androgen insensitivity syndrome and Sertoli cell adenoma. Int J Gynecol Pathol 2001;20:196–199.PubMedGoogle Scholar
  178. 178.
    Mene MP, Finkelstein LH, Manfrey SJ, et al. Metastatic Sertoli cell carcinoma of the testis. J Am Osteopath Assoc 1996;96:612–614.PubMedGoogle Scholar
  179. 179.
    Nonomura K, Koyama T, Kakizaki H, et al. Testicular-sparing surgery for the prepubertal testicular tumor. Experience of two cases with large cell calcifying Sertoli cell tumors. Eur Urol 2001;40:699–704.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2005

Authors and Affiliations

  • Chris M. Bacon
    • 1
  • Alex Freeman
    • 1
  1. 1.Department of HistopathologyRoyal Free and University College, Medical SchoolLondonUK

Personalised recommendations